Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL22092129

NCC(Cn1nc2ccc(Br)cn2c1=O)=C(F)F.O=C(O)C(F)(F)F

nearest known ligand 0.45

Full drug profile on Sugi Atlas →

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ GPR139 Q6DWJ6 15/20 0.45
▸ PDE10A Q9Y233 1/20 0.39
▸ SLC5A1 P13866 1/20 0.35
▸ SLC5A2 P31639 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.31
▸ MEN1 O00255 1/20 0.31
▸ POLB P06746 1/20 0.31
▸ RECQL P46063 1/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ RXFP1 Q9HBX9 1/20 0.31
▸ TDP1 Q9NUW8 1/20 0.31
▸ L3MBTL1 Q9Y468 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22092249 0.92 GPR139 (0.48) GPR139PDE10ASLC5A1SLC5A2KDM4E
Trifluoroacetic Acid SCHEMBL22092064 0.84 GPR139 (0.36) GPR139
Trifluoroacetic Acid SCHEMBL22092248 0.78 GPR139 (0.46) GPR139PDE10A
SCHEMBL22206303 0.75 GPR139 (0.47) GPR139PDE10ASLC5A1SLC5A2KDM4E
SCHEMBL22098778 0.75 GPR139 (0.38) GPR139
SCHEMBL22206337 0.74 GPR139 (0.46) GPR139PDE10AKDM4ERXFP1
Hydrochloric Acid SCHEMBL22206372 0.74 GPR139 (0.47) GPR139PDE10ASLC5A1SLC5A2KDM4E
SCHEMBL17141321 0.70 GPR139 (0.58) GPR139PDE10ASLC5A1SLC5A2KDM4E
SCHEMBL17141252 0.70 GPR139 (0.56) GPR139PDE10ASLC5A1SLC5A2KDM4E
Trifluoroacetic Acid SCHEMBL22091224 0.70 PPARD (0.35) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11820769-B2 Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same YUHAN CORPORATION (KR) 2023-11-21 — — US disclosed
US-20220024918-A1 TRIAZOLOPYRIDIN-3-ONES OR THEIR SALTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME YUHAN CORPORATION (KR) 2022-01-27 — — US disclosed
EP-3894408-A1 TRIAZOLOPYRIDIN-3-ONES OR THEIR SALTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME Yuhan Corporation (KR) 2021-10-20 — — EP disclosed
US-11091479-B2 Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same YUHAN CORPORATION (KR) 2021-08-17 — — US disclosed
US-20200223844-A1 TRIAZOLOPYRIDIN-3-ONES OR THEIR SALTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME YUHAN CORPORATION (KR) 2020-07-16 — — US disclosed
WO-2020121263-A1 TRIAZOLOPYRIDIN-3-ONES OR THEIR SALTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME YUHAN CORPORATION (KR) 2020-06-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11091479-B2 Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same VAPB, HDLBP, VAPA GPR139 4033/4885PDE10A 4028/4885SLC5A1 64/4885
US-11820769-B2 Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same VAPB, HDLBP, VAPA GPR139 4033/4885PDE10A 4028/4885SLC5A1 64/4885
US-20200223844-A1 TRIAZOLOPYRIDIN-3-ONES OR THEIR SALTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME VAPB, HDLBP, VAPA GPR139 4033/4885PDE10A 4028/4885SLC5A1 64/4885
US-20220024918-A1 TRIAZOLOPYRIDIN-3-ONES OR THEIR SALTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME VAPB, HDLBP, VAPA GPR139 4033/4885PDE10A 4028/4885SLC5A1 64/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback